These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2189429)

  • 1. Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial.
    Jenike MA; Albert M; Baer L; Gunther J
    J Geriatr Psychiatry Neurol; 1990; 3(1):13-6. PubMed ID: 2189429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term administration of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
    van Dyck CH; Newhouse P; Falk WE; Mattes JA
    Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type.
    Möller H-J ; Hampel H; Hegerl U; Schmitt W; Walter K
    Pharmacopsychiatry; 1999 May; 32(3):99-106. PubMed ID: 10463377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.
    Beller SA; Overall JE; Swann AC
    Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
    Thal LJ; Masur DM; Blau AD; Fuld PA; Klauber MR
    J Am Geriatr Soc; 1989 Jan; 37(1):42-8. PubMed ID: 2642499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral physostigmine as treatment for dementia of the Alzheimer type: a long-term outpatient trial.
    Jenike MA; Albert MS; Baer L
    Alzheimer Dis Assoc Disord; 1990; 4(4):226-31. PubMed ID: 2264980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
    Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A
    Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type.
    Sevush S; Guterman A; Villalon AV
    J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease.
    Sano M; Bell K; Marder K; Stricks L; Stern Y; Mayeux R
    Clin Neuropharmacol; 1993 Feb; 16(1):61-9. PubMed ID: 8422658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease.
    Bierer LM; Aisen PS; Davidson M; Ryan TM; Stern RG; Schmeidler J; Davis KL
    Alzheimer Dis Assoc Disord; 1993; 7(2):98-104. PubMed ID: 8347333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease.
    Thal LJ; Ferguson JM; Mintzer J; Raskin A; Targum SD
    Neurology; 1999 Apr; 52(6):1146-52. PubMed ID: 10214735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral physostigmine treatment of patients with Alzheimer's disease.
    Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL
    Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of long-term physostigmine administration in Alzheimer's disease.
    Harrell LE; Callaway R; Morere D; Falgout J
    Neurology; 1990 Sep; 40(9):1350-4. PubMed ID: 2392216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memory enhancement with oral physostigmine in Alzheimer's disease.
    N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral physostigmine and lecithin improve memory in Alzheimer disease.
    Thal LJ; Fuld PA; Masur DM; Sharpless NS
    Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease.
    Imbimbo BP; Troetel WM; Martelli P; Lucchelli F
    Dement Geriatr Cogn Disord; 2000; 11(1):17-24. PubMed ID: 10629357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
    Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL
    Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.